Literature DB >> 11854848

Stimulation of Lipogenesis by Interleukin-6 and Misoprostol-Free Acid in Isolated Rat Hepatocytes.

Eric P. Brass1, William H. Vetter.   

Abstract

Recent work has established that Kupffer cell products, including prostaglandins, can act directly on hepatocytes to modify glucose and lipid metabolism. Additionally, prostaglandins can act on Kupffer cells to modify the expression of cytokines. Interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) stimulate hepatic lipogenesis following in vivo administration. To define the direct effects of these cytokines on lipogenesis in primary culture rat hepatocytes, hepatocytes were cultured in the presence of IL-6 or TNF-alpha for periods of 24--72 h. IL-6 caused an increase in hepatocyte lipogenic capacity (56% increase by 12.5 ng ml(minus sign1) IL-6 after 72 h of cytokine exposure). The increase in cellular lipogenic capacity was confirmed using (3)H2O as the radiotracer. TNF-alpha did not increase the rate of hepatocyte lipogenesis. Neither IL-6 nor TNF-alpha modified rates of lipogenesis upon acute exposure to the cytokine. Misoprostol-free acid (0.1 &mgr;M) acutely increased hepatocyte lipogenic rates by 14% in the presence of glucagon. These results demonstrate that IL-6 can act directly on hepatocytes to induce lipogenic capacity and that E-series prostaglandins can antagonize the acute inhibition of lipogenesis by glucagon. Because IL-6 is produced by Kupffer cells, and its expression is modulated by prostaglandins, the Kupffer cell is a novel target for prostaglandin therapy. Administration of prostaglandins may provide a novel strategy for pharmacologic therapy of disorders of glucose or lipid metabolism.

Entities:  

Year:  1995        PMID: 11854848     DOI: 10.1097/00045391-199509000-00019

Source DB:  PubMed          Journal:  Am J Ther        ISSN: 1075-2765            Impact factor:   2.688


  4 in total

1.  Single administration of recombinant IL-6 restores the gene expression of lipogenic enzymes in liver of fasting IL-6-deficient mice.

Authors:  A L Gavito; R Cabello; J Suarez; A Serrano; F J Pavón; M Vida; M Romero; V Pardo; D Bautista; S Arrabal; J Decara; A L Cuesta; A M Valverde; F Rodríguez de Fonseca; E Baixeras
Journal:  Br J Pharmacol       Date:  2016-02-22       Impact factor: 8.739

2.  Dietary effects on liver tumor burden in mice treated with the hepatocellular carcinogen diethylnitrosamine.

Authors:  Marin E Healy; Jenny D Y Chow; Frances L Byrne; David S Breen; Norbert Leitinger; Chien Li; Carolin Lackner; Stephen H Caldwell; Kyle L Hoehn
Journal:  J Hepatol       Date:  2014-10-23       Impact factor: 25.083

3.  Chronic administration of recombinant IL-6 upregulates lipogenic enzyme expression and aggravates high-fat-diet-induced steatosis in IL-6-deficient mice.

Authors:  Margarita Vida; Ana Luisa Gavito; Francisco Javier Pavón; Dolores Bautista; Antonia Serrano; Juan Suarez; Sergio Arrabal; Juan Decara; Miguel Romero-Cuevas; Fernando Rodríguez de Fonseca; Elena Baixeras
Journal:  Dis Model Mech       Date:  2015-05-14       Impact factor: 5.758

4.  Chronic IL-6 Administration Desensitizes IL-6 Response in Liver, Causes Hyperleptinemia and Aggravates Steatosis in Diet-Induced-Obese Mice.

Authors:  Ana Luisa Gavito; Dolores Bautista; Juan Suarez; Samir Badran; Rocío Arco; Francisco Javier Pavón; Antonia Serrano; Patricia Rivera; Juan Decara; Antonio Luis Cuesta; Fernando Rodríguez-de-Fonseca; Elena Baixeras
Journal:  PLoS One       Date:  2016-06-22       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.